Latest Breaking News On - லேபேர் பிறவி - Page 1 : comparemela.com

Prevent Blindness Declares Second Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 16-22

Prevent Blindness Declares Second Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 16-22 Share Article National nonprofit group, Prevent Blindness, continues to educate public on importance of genetic testing, various types of retinal diseases, and support resources available. Prevent Blindness declares May 16-22, 2021, as it s second annual “Inherited Retinal Disease (IRD) Genetic Testing Week” “By encouraging the public to educate themselves about IRDs and the positive impact that genetic testing may have on their health, we hope to save sight for patients in the near term and throughout their lives,” said Jeff Todd, president and CEO of Prevent Blindness.

United statesJeff toddAmerican society of gene cell therapyPrevent blindnessRetinal diseaseGenetic testingInherited retinal diseasesRetinitis pigmentosaStargardt diseaseCone rod dystrophyLeber congenitalAmerican societyCell therapyEye wantSpark therapeuticsTesting week

OCGN Stock Is Preparing to Move Far Past Its All-Time High

Ocugen Stock Is Preparing to Move Far Past Its All-Time High Orphan drug designation is precisely the boost that OCGN stock needed Mar 3, 2021, 7:54 am EDT March 3, 2021 Ocugen (NASDAQ: Bharat Biotech on the development of Bharat’s Covid-19 vaccine candidate, which is something that is certain to move OCGN stock. Source: Shutterstock If there’s anything that biotech company investors want to see, it’s approval from regulators. That’s the type of event that can push a biotech stock to its previous high point and beyond. American-based investors shouldn’t only be on the lookout for approval from the U.S. Food and Drug Administration (FDA). In Ocugen’s case, approval from other geographies can also be quite significant.

United statesBharat covidMohamed geneadNasdaq exchangeEuropean unionEuropean commissionDrug administrationBharat biotechCloser lookLeber congenitalRetina scientific advisory boardActing chief medical officerஒன்றுபட்டது மாநிலங்களில்நாஸ்டாக் பரிமாற்றம்ஐரோப்பிய தொழிற்சங்கம்ஐரோப்பிய தரகு

Ocugen s inherited retinal disease gene therapy OCU400 wins orphan status

Ocugen’s inherited retinal disease gene therapy OCU400 wins orphan status 24th February 2021 OCU400 is a novel investigational gene therapy based on Ocugen’s modifier gene therapy platform. It consists of a functional copy of the nuclear hormone receptor gene NR2E3 and is delivered to target cells in the retina using an adeno-associated viral (AAV) vector. In a statement, Ocugen said that nuclear hormone receptors such as NR2E3 are important modulators of retinal development and function. Delivering a functional copy of NR2E3 directly into target cells within the retina could help restart retinal homeostasis, stabilising cells and potentially rescuing photoreceptors from degeneration.

Mohamed geneadEuropean commissionLeber congenitalInherited retinal diseaseGene therapyஐரோப்பிய தரகுலேபேர் பிறவிபரம்பரை விழித்திரை நோய்கீந் சிகிச்சை

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis

European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis NR2E3), for the treatment of both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA). The prevalence of RP in Europe is estimated at approximately 165,000 patients and the prevalence of LCA in Europe is estimated at approximately 40,000 patients. Globally, the number of people suffering from RP and LCA is estimated to be around 2.0 million and 0.2 million, respectively. We believe the granting of this designation by the European Commission validates the potential of our modifier gene therapy platform to treat many inherited retinal diseases, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen.

United statesNeena haiderSanjay subramanianEmmie twomblyMohamed geneadProfessor of ophthalmology at harvard medical schoolEuropean commissionSchepens eye research instituteOcugen incExchange commissionHead of corporate developmentNuclear hormone receptorsEuropean unionLeber congenitalChief executive officerRetina scientific advisory board

(OCGN) - Ocugen s Vision Loss Gene Therapy Receives Orphan Drug Tag In Europe

(OCGN) - Ocugen s Vision Loss Gene Therapy Receives Orphan Drug Tag In Europe
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

European commissionOcugen incOrphan medicinal productLeber congenitalBharat biotechஐரோப்பிய தரகுஆர்ஃபந் மருத்துவ ப்ராடக்ட்லேபேர் பிறவிபாரத் பயோடெக்